vs

Side-by-side financial comparison of POTLATCHDELTIC CORP (PCH) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

POTLATCHDELTIC CORP is the larger business by last-quarter revenue ($314.2M vs $207.3M, roughly 1.5× Ultragenyx Pharmaceutical Inc.). POTLATCHDELTIC CORP runs the higher net margin — 8.2% vs -62.0%, a 70.3% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 23.1%). POTLATCHDELTIC CORP produced more free cash flow last quarter ($50.1M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 11.1%).

PotlatchDeltic Corporation is an American diversified forest products company based in Spokane, Washington.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

PCH vs RARE — Head-to-Head

Bigger by revenue
PCH
PCH
1.5× larger
PCH
$314.2M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+2.7% gap
RARE
25.9%
23.1%
PCH
Higher net margin
PCH
PCH
70.3% more per $
PCH
8.2%
-62.0%
RARE
More free cash flow
PCH
PCH
$150.9M more FCF
PCH
$50.1M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
11.1%
PCH

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
PCH
PCH
RARE
RARE
Revenue
$314.2M
$207.3M
Net Profit
$25.9M
$-128.6M
Gross Margin
18.2%
Operating Margin
11.2%
-54.7%
Net Margin
8.2%
-62.0%
Revenue YoY
23.1%
25.9%
Net Profit YoY
682.5%
3.5%
EPS (diluted)
$0.33
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PCH
PCH
RARE
RARE
Q4 25
$207.3M
Q3 25
$314.2M
$159.9M
Q2 25
$275.0M
$166.5M
Q1 25
$268.3M
$139.3M
Q4 24
$258.1M
$164.6M
Q3 24
$255.1M
$139.5M
Q2 24
$320.7M
$147.0M
Q1 24
$228.1M
$108.8M
Net Profit
PCH
PCH
RARE
RARE
Q4 25
$-128.6M
Q3 25
$25.9M
$-180.4M
Q2 25
$7.4M
$-115.0M
Q1 25
$25.8M
$-151.1M
Q4 24
$5.2M
$-133.2M
Q3 24
$3.3M
$-133.5M
Q2 24
$13.7M
$-131.6M
Q1 24
$-305.0K
$-170.7M
Gross Margin
PCH
PCH
RARE
RARE
Q4 25
Q3 25
18.2%
Q2 25
13.0%
Q1 25
17.8%
Q4 24
13.4%
Q3 24
10.8%
Q2 24
11.9%
Q1 24
7.0%
Operating Margin
PCH
PCH
RARE
RARE
Q4 25
-54.7%
Q3 25
11.2%
-106.9%
Q2 25
5.0%
-64.8%
Q1 25
10.3%
-102.6%
Q4 24
5.2%
-74.3%
Q3 24
2.8%
-94.6%
Q2 24
5.4%
-79.1%
Q1 24
-2.1%
-151.9%
Net Margin
PCH
PCH
RARE
RARE
Q4 25
-62.0%
Q3 25
8.2%
-112.8%
Q2 25
2.7%
-69.0%
Q1 25
9.6%
-108.5%
Q4 24
2.0%
-80.9%
Q3 24
1.3%
-95.7%
Q2 24
4.3%
-89.5%
Q1 24
-0.1%
-156.8%
EPS (diluted)
PCH
PCH
RARE
RARE
Q4 25
$-1.28
Q3 25
$0.33
$-1.81
Q2 25
$0.09
$-1.17
Q1 25
$0.33
$-1.57
Q4 24
$0.07
$-1.34
Q3 24
$0.04
$-1.40
Q2 24
$0.17
$-1.52
Q1 24
$0.00
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PCH
PCH
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$88.8M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$-80.0M
Total Assets
$3.2B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PCH
PCH
RARE
RARE
Q4 25
$421.0M
Q3 25
$88.8M
$202.5M
Q2 25
$95.3M
$176.3M
Q1 25
$147.5M
$127.1M
Q4 24
$151.6M
$174.0M
Q3 24
$161.1M
$150.6M
Q2 24
$199.7M
$480.7M
Q1 24
$180.2M
$112.3M
Total Debt
PCH
PCH
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
PCH
PCH
RARE
RARE
Q4 25
$-80.0M
Q3 25
$1.9B
$9.2M
Q2 25
$1.9B
$151.3M
Q1 25
$2.0B
$144.2M
Q4 24
$2.0B
$255.0M
Q3 24
$2.1B
$346.8M
Q2 24
$2.1B
$432.4M
Q1 24
$2.2B
$140.3M
Total Assets
PCH
PCH
RARE
RARE
Q4 25
$1.5B
Q3 25
$3.2B
$1.2B
Q2 25
$3.2B
$1.3B
Q1 25
$3.3B
$1.3B
Q4 24
$3.3B
$1.5B
Q3 24
$3.3B
$1.5B
Q2 24
$3.4B
$1.6B
Q1 24
$3.4B
$1.3B
Debt / Equity
PCH
PCH
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.51×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PCH
PCH
RARE
RARE
Operating Cash FlowLast quarter
$65.7M
$-99.8M
Free Cash FlowOCF − Capex
$50.1M
$-100.8M
FCF MarginFCF / Revenue
15.9%
-48.6%
Capex IntensityCapex / Revenue
4.9%
0.5%
Cash ConversionOCF / Net Profit
2.54×
TTM Free Cash FlowTrailing 4 quarters
$132.4M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PCH
PCH
RARE
RARE
Q4 25
$-99.8M
Q3 25
$65.7M
$-91.4M
Q2 25
$41.0M
$-108.3M
Q1 25
$49.1M
$-166.5M
Q4 24
$45.4M
$-79.3M
Q3 24
$26.5M
$-67.0M
Q2 24
$100.6M
$-77.0M
Q1 24
$16.0M
$-190.7M
Free Cash Flow
PCH
PCH
RARE
RARE
Q4 25
$-100.8M
Q3 25
$50.1M
$-92.7M
Q2 25
$30.6M
$-110.7M
Q1 25
$26.3M
$-167.8M
Q4 24
$25.4M
$-79.5M
Q3 24
$-8.2M
$-68.6M
Q2 24
$72.4M
$-79.0M
Q1 24
$2.0M
$-193.9M
FCF Margin
PCH
PCH
RARE
RARE
Q4 25
-48.6%
Q3 25
15.9%
-58.0%
Q2 25
11.1%
-66.5%
Q1 25
9.8%
-120.5%
Q4 24
9.9%
-48.3%
Q3 24
-3.2%
-49.2%
Q2 24
22.6%
-53.7%
Q1 24
0.9%
-178.2%
Capex Intensity
PCH
PCH
RARE
RARE
Q4 25
0.5%
Q3 25
4.9%
0.8%
Q2 25
3.8%
1.5%
Q1 25
8.5%
1.0%
Q4 24
7.7%
0.1%
Q3 24
13.6%
1.2%
Q2 24
8.8%
1.4%
Q1 24
6.1%
3.0%
Cash Conversion
PCH
PCH
RARE
RARE
Q4 25
Q3 25
2.54×
Q2 25
5.58×
Q1 25
1.90×
Q4 24
8.74×
Q3 24
7.99×
Q2 24
7.35×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PCH
PCH

Lumber$131.8M42%
Timberlands$52.5M17%
Rural Real Estate$51.3M16%
Residuals And Panels$34.0M11%
Pulpwood$16.7M5%
Development Real Estate$14.6M5%
Other$8.1M3%
Other Products$5.2M2%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons